Small Cell Lung Cancer
Articles tagged with Small Cell Lung Cancer
A simple X-ray measure linked to survival in lung cancer surgery patients
Researchers find biomarker of chemotherapy resistance in relapsed lung cancer
Researchers have discovered a biomarker for chemotherapy resistance in small cell lung cancer, which can help identify cells that become more invasive and lead to treatment resistance. Targeting these cells with YAP1 may be a possible strategy to improve patient outcomes.
Alliance study shows new promise against locally advanced lung cancer
A study by the Alliance Foundation Trials shows that combining immunotherapy and chemotherapy before surgery can help more patients with locally advanced non-small cell lung cancer undergo complete cancer resection, improving their long-term health. The treatment also led to high rates of lymph node clearance and successful surgical re...
A lung cancer that changes its identity may be hiding in plain sight
A new study maps how rare mixed tumors evolve into hybrid cell states and immune-protected neighborhoods, pointing to new ways to detect and treat combined small-cell lung cancer. The findings reveal that these tumors do not arise from two separate cancers but rather from a single ancestral cell that evolves over time.
NRG Oncology/Alliance trial finds immunotherapy did not improve survival when added to chemoradiotherapy for small cell lung cancer
The NRG-LU005 trial found that immunotherapy atezolizumab did not improve survival for patients with limited-stage small cell lung cancer when added to chemoradiation. Twice-daily radiation therapy, however, was associated with improved survival in this population.
Study points to potential new therapies for hard-to-treat lung cancers
Researchers found that inhibiting glucose transport can overcome tumor resistance to chloroquine treatment by inducing mitochondrial damage and oxidative stress. The study suggests a new combination therapy strategy for treating lung squamous cell carcinoma and subsets of adenocarcinoma with limited treatment options.
Lymph node examination should be expanded to accurately assess cancer spread in patients with lung cancer
Breakthrough research recommends that more than one N1 node be removed and evaluated during surgery for non-small cell lung cancer (NSCLC). The study found that many cancers were identified in N1 nodes adjacent to the bronchi, highlighting the need for expanded lymph node evaluation.
Hope for smarter lung cancer care
A study from Flinders University found that patients with progressive disease, which describes the way cancer grows, have varying survival rates depending on whether their existing tumours re-grow or new ones appear. Understanding this progression can help doctors make better decisions about future treatment strategies.
Singapore scientists discover lung cancer's "bodyguard system" - and how to disarm it
Researchers identify a molecular target that enhances treatment for EGFR-mutant lung cancers prevalent in Asia. Disrupting this protective system can shrink tumors in laboratory models.
Blood test predicts which patients with lung cancer will benefit from newly approved immunotherapy drug
A new blood test has been developed to predict which patients with lung cancer will benefit from the newly approved immunotherapy drug tarlatamab. The test, based on circulating tumor cells, correctly identified 85% of patients who responded to the drug and 100% of those who did not.
UH pharmacy researcher receives $900,000 CPRIT grant to develop nanodrug that boosts immune system to fight cancer
A new nanodrug called Nano-273 could offer improved survival for patients with pancreatic and lung cancers by activating the immune system and blocking tumor growth. The drug, developed by University of Houston researcher Wei Gao, has shown promising results in early studies.
Efficacy and safety of immune checkpoint inhibitors in EGFR-mutant NSCLC patients with EGFR-TKI resistance: an updated systematic review and meta-analysis
ICIs combined with chemotherapy shows promise for treating EGFR-TKI-resistant NSCLC, improving PFS and OS. Acceptable safety profile for ICIs-chemotherapy regimen, suggesting potential as therapeutic option.
Shapeshifting cancers’ masters, unmasked
Cancer researchers at Cold Spring Harbor Laboratory have identified key proteins that determine the behavior of two hard-to-treat carcinomas, pancreatic cancer and tuft cell lung cancer. These findings could lead to new therapies targeting specific vulnerabilities in these cancers.
Higher glycemic index linked to higher lung cancer risk
A population-based cohort study found that individuals following high-glycemic index diets had a 13% higher chance of developing lung cancer compared to those on low-GI diets. In contrast, those consuming high-glycemic load diets experienced a 28% lower risk of lung cancer.
City of Hope appoints leading lung cancer expert Dr. Christine M. Lovly to head national thoracic oncology program
Dr. Lovly brings nearly two decades of experience in clinical care, research and academic leadership to her new role, shaping the modern landscape of lung cancer care. Her expertise in precision medicine will be instrumental in accelerating progress for patients with lung cancer across the country.
Winners of the ASTRO-AstraZeneca small cell lung cancer therapy challenge announced
The American Society for Radiation Oncology (ASTRO) has announced three winning research proposals for the 2025 ASTRO-AstraZeneca Small Cell Lung Cancer Therapy Challenge. The selected projects aim to improve therapies and outcomes for patients with limited-stage SCLC through immunotherapy and radiation techniques.
New study may transform diagnosis of Britain’s number one cancer
A new study may transform the diagnosis of Britain's number one cancer, lung cancer. Researchers are investigating whether low-dose CT scans can detect lung cancers earlier than current chest X-rays. The study aims to identify which patients would benefit from these more accurate scans.
Chemotherapy combination boosts overall survival in patients with EGFR-mutant non-small cell lung cancer
The phase 3 FLAURA2 study shows that adding platinum-pemetrexed to osimertinib improves overall survival in patients with newly diagnosed EGFR-mutated advanced NSCLC. Median overall survival was 47.5 months, compared to 37.6 months with osimertinib alone.
University of Calgary scientists want your toenail clippings for a study related to lung cancer
Researchers are collecting toenail clippings from Canadians to estimate a person's lung-cancer risk based on long-term radon exposure. The study aims to provide critical data for early screening and diagnosis of lung cancer.
Journal of Thoracic Oncology study recommends new grading system for invasive squamous cell carcinoma of the lung
A new grading system for invasive squamous cell carcinoma of the lung has been proposed based on tumor budding, with tumors classified as low-grade (0-9 buds/0.785 mm²) or high-grade (≥10 buds/0.785 mm²). The system was validated in a test set and demonstrated improved prognostic accuracy and guide treatment decisions.
Patient-reported outcome analysis of NRG Oncology trial in limited-stage small cell lung cancer suggests quality of life benefit with twice - (vs once -) daily radiation
A patient-reported outcomes analysis suggests that twice-daily radiation is associated with better quality of life and longer survival compared to once-daily radiation in patients with limited-stage small cell lung cancer. The study found less clinically meaningful decline in quality of life among those receiving twice-daily radiation.
Basal stem-like cells identified as origin of small cell lung cancer in lab models
Researchers identify basal stem-like cells as the origin of small cell lung cancer, providing a major shift in understanding this deadly disease. The study's findings allow for exploration of strategies to prevent the disease before it evades the immune system and spreads.
Lung cancer cells in the brain form electrical connections with neurons that spur tumor growth
Researchers discover lung cancer cells in the brain form synapses with neurons, promoting tumor growth. This finding highlights the importance of neural signaling in cancer growth and suggests novel therapies to interrupt this signaling.
Wired to grow: How small cell lung cancer hijacks neuronal synapses
Researchers found that lung cancer cells can form functional synapses with neurons, supporting their growth and survival. Disrupting glutamate signalling led to lower tumour burden and longer survival in experimental mice, highlighting promising therapeutic targets.
New research identifies IFITM3 as key driver of immunotherapy response in small cell lung cancer
Research presents IFITM3 as critical regulator of immunotherapy sensitivity in small cell lung cancer (SCLC), offering a promising new avenue for overcoming resistance to PD-1/PD-L1 checkpoint blockade. Enhanced MHC-I expression improves antigen presentation and boosts CD8⁺ T cell infiltration.
Speed isn’t everything when it comes to covalent inhibitor drugs, study finds
Researchers found that a faster rate of binding does not always translate to greater potency, as the study's lead author David Heppner explained. The team proposed a two-step design process balancing inactivation efficiency rates with target selectivity and other parameters to identify promising compounds.
Study advances understanding of rare type of lung cancer
A recent study published in Nature Communications provides a comprehensive characterization of Large Cell Neuroendocrine Carcinoma (LCNEC), a rare and aggressive type of lung cancer. The research team analyzed data from 590 patients and found that LCNEC shares features with other types of lung cancer, yet has distinct aspects. They ide...
Five-year analysis shows immunotherapy plus chemotherapy before lung cancer surgery significantly improves long-term survival
A five-year analysis of the CheckMate-816 clinical trial shows that immunotherapy plus chemotherapy before lung cancer surgery significantly improves long-term survival. Patients who achieved complete remission had a 95% five-year survival rate.
Relationship between mutation profile detected by next-generation sequencing and histopathological parameters in lung squamous cell carcinoma
The study evaluated the mutation profiles of lung squamous cell carcinoma (LSCC) detected by next-generation sequencing to assess relationships with clinicopathological parameters. Detection of mutations revealed associations between certain genes, such as PIK3CA and NF1, with specific histopathological features.
AACR 2025: Colon cancer risk reduction, predicting melanoma spread and new drug therapies among Ohio State findings
Researchers at Ohio State University have identified new targeted therapies for treating small cell lung cancer, predicting melanoma spread, and reducing endometrial cancer risk. A 31-gene expression profile has been developed to identify patients at high risk of melanoma spread, allowing for closer monitoring and earlier treatment.
CHEST Critical Care and CHEST Pulmonary receive indexation with Scopus
The American College of Chest Physicians' CHEST Critical Care and CHEST Pulmonary journals have been indexed in Elsevier's Scopus database. This achievement is a testament to the high-quality research published in these journals, which provide open access content in pulmonary and critical care medicine.
Induction chemotherapy followed by camrelizumab plus apatinib and chemotherapy demonstrates promising antitumor activity with acceptable safety as first-line treatment for extensive-stage small-cell lung cancer: A multicenter, single-arm trial
A single-arm trial evaluated the safety and efficacy of first-line camrelizumab, apatinib, and chemotherapy in untreated extensive-stage small-cell lung cancer patients. The treatment demonstrated an ORR of 88.9% and median PFS and OS of 7.3 and 17.3 months, respectively.
European Lung Cancer Congress 2025: Event announcement
The European Lung Cancer Congress 2025 will take place in Paris from March 26-29, featuring renowned experts discussing the latest research on lung cancer prevention, diagnosis, and treatment. The congress will also include award lectures and live streaming of the event.
Lung cancer cells can go ‘off grid’
Researchers found that aggressive lung cancer cells can generate their own electrical activity, building an independent network within the tumour. This property is distinct from most other cancer types and may drive the tumour's ability to grow and spread.
MD Anderson’s Lauren Averett Byers receives TAMEST O’Donnell Award for seminal contributions to lung cancer research
Lauren Averett Byers, a professor at MD Anderson Cancer Center, has received the 2025 Edith and Peter O'Donnell Award in Medicine from Texas Academy of Medicine, Engineering, Science and Technology (TAMEST) for her fundamental discoveries in small cell lung cancer. Her work has led to personalized treatments and improved patient outcomes.
New PROSPECT-lung trial launches to advance treatment options for operable non-small cell lung cancer
The PROSPECT-Lung trial evaluates the role of immunotherapy before and after surgery in resectable non-small cell lung cancer patients. The trial aims to determine whether adding immune checkpoint inhibitors to standard chemotherapy improves survival outcomes.
Combination approach shows promise for treating rare, aggressive cancers
Researchers at UCLA Health Jonsson Comprehensive Cancer Center have shown that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve treatment outcomes for patients with advanced small cell bladder cancer and small cell/neuroendocrine prostate cancer. The study found that the combination treatment resul...
Precision medicine in SCLC: DLL3, ASC1, TTF-1, and Ki-67 expression
Researchers analyzed tumor samples from 64 SCLC patients, identifying promising results for biomarkers DLL3 and TTF-1. These biomarkers showed potential as targets for therapies like Tarlatamab and improved survival rates in patients with TTF-1-positive tumors.
NRG Oncology trial implies the addition of atezolizumab concurrently to standard of care does not improve survival in limited-stage small cell lung cancer
The NRG Oncology trial found that atezolizumab given concurrently with chemoradiation did not improve overall survival for patients with limited-stage small cell lung cancer. However, the study suggests that LS-SCLC patients benefit from immunotherapy when given after completion of chemoradiation.
Timing matters when adding immunotherapy to chemoradiation for patients with limited-stage small cell lung cancer
A new trial suggests that adding immunotherapy to chemoradiation can extend survival in patients with limited-stage small cell lung cancer. However, the findings also indicate that delivering the treatments at different times yields varying results, with concurrent treatment not offering improved survival benefits.
New, rare type of small cell lung cancer identified by MSK research team
A new subtype of small cell lung cancer has been identified that primarily affects younger people who have never smoked. The disease has distinct clinical and pathological features, and a unique molecular mechanism involving chromothripsis-mediated DNA damage.
Study: Some lung cancer disparities lessen in south Florida
A new study found that Hispanic non-small cell lung cancer patients in South Florida tend to be diagnosed at earlier stages than White patients, with a lower likelihood of advanced-stage diagnoses. This disparity disappears when examining ethnic subpopulations within the Hispanic population.
New findings on possible therapies to target oncogenic transcription factors in multiple cancer types
A new study from Michigan Medicine suggests that inhibiting the SWI/SNF epigenetic complex can therapeutically target oncogenic transcription factors. The research, led by Arul Chinnaiyan, builds on previous work to find genetic vulnerabilities in transcription factor-driven cancers.
The role of RNF114B, a key gene in the progression and treatment of lung adenocarcinoma, has been discovered
The study identified RNF144B as a tumour suppressor that prevents genomic instability, but low expression leads to poor prognosis and treatment resistance in lung adenocarcinoma. The research suggests that even non-mutated genes like RNF144B can have a significant impact on cancer development.
Splicing it all together in the fight against cancer
Researchers at Osaka University have developed molecules that can correct improper splicing of a vital tumor suppressor gene in neuroendocrine cancers. The study demonstrates that these splice-switching oligonucleotides can significantly reduce viable cancer cells and tumor size in mice, suggesting a novel therapeutic approach for intr...
Scientists unravel mystery of drug response in small cell lung cancer
A research team at the University of Cologne has identified mechanisms governing drug response in small cell lung cancer. The study reveals that large populations of treatment-sensitive cells often hide numerous therapy-resistant cells that can multiply unchecked after successful treatment.
How one type of lung cancer can transform into another
Researchers at Weill Cornell Medicine have developed a mouse model that illuminates the process of histological transformation, where adenocarcinoma transforms into aggressive small cell lung cancer. The study suggests targeting Myc proteins as potential therapeutic approaches for this deadly type of cancer.
Protein identified as a potential biomarker and therapeutic target for aggressive neuroendocrine carcinomas
Researchers have identified UCHL1, a protein found in highly aggressive neuroendocrine carcinomas and neuroblastoma, as a potential molecular biomarker for diagnosing these cancers and predicting responses to therapy. Targeting UCHL1 with inhibitors has been shown to delay the growth and spread of these tumors in pre-clinical models.
Lung cancer cells covertly thrive in brain under guise of protection, Stanford Medicine study finds
Small cell lung cancers metastasize to the brain by convincing astrocytes they are baby neurons in need of protection. Blocking this signal may slow or stop brain metastasis growth, according to a Stanford Medicine study.
Lurbinectedin for Neuroendocrine Tumors (NETs)
Researchers discuss lurbinectedin as a method to treat neuroendocrine tumors (NETs), with encouraging results from phase II basket studies demonstrating activity in platinum-sensitive relapsed SCLC and other malignancies. Lurbinectedin's mechanism of action involves inhibiting oncogenic transcription, promoting apoptosis and cell death.
Small cell lung cancer: new approach to overcoming chemo-resistance
Researchers from MedUni Vienna developed a new approach to fighting resistant cell lines in small cell lung cancer by combining two already available therapeutic agents. The study reveals the molecular mechanism underlying therapy resistance and provides a promising basis for research into successful new therapies.
OSE Immunotherapeutics announces: positive phase 3 data from its cancer vaccine in lung cancer patients with resistance to previous immunotherapy published in Annals of Oncology
Tedopi, a T-cell epitope-based cancer vaccine, has demonstrated improved overall survival and a better safety profile compared to chemotherapy in HLA-A2 positive patients with advanced or metastatic NSCLC who have progressed after immune checkpoint inhibitors. The Phase 3 trial showed a significant reduction in the risk of death by 41%.
Significant progress in small-cell lung cancer research
Researchers at MedUni Vienna's Department of Thoracic Surgery have made key findings in small-cell lung cancer, including the identification of tumor subgroups associated with varying clinical behaviors. They also propose promising therapeutic strategies for patients with characteristic molecular profiles.
Results of SWOG S1929 trial show patients with small-cell lung cancer with SLFN11 expression can benefit from PARP inhibitor added to immune checkpoint blockade
A phase II trial showed that patients with extensive stage SCLC expressing the Schlafen-11 gene had significantly longer progression-free survival when treated with atezolizumab and talazoparib. The study demonstrates improved outcomes for patients with SLFN11-positive SCLC, paving the way for personalized therapy approaches.
Novel PET agent effectively detects multiple cancers, identifies patients for targeted therapies
A new molecular imaging radiotracer, <sup> 68 </sup> Ga-PentixaFor, demonstrates high image contrast in various cancers, including hematologic malignancies and small cell lung cancer. This agent targets the C-X-C motif chemokine receptor 4 (CXCR4), which is a predictor of poor prognosis in cancer patients.
Small cell lung cancer: New approaches to personalized treatment
A new study reveals that different SCLC subtypes have specific molecular characteristics, leading to varying responses to cancer treatment. The research provides a basis for developing targeted and personalized treatment approaches tailored to each subtype.
New gene target for aggressive lung cancer discovered
Scientists at Northwestern University have identified a new gene that activates an aggressive subtype of small-cell lung cancer with no current effective treatment. Deleting this gene kills cancer cells in deadly subtype.
Drug combo therapy in mice blocks drug resistance, halts tumor growth
Researchers discovered that combining a new target with an old chemotherapy drug can reduce resistance and potentially improve treatment outcomes for small cell lung cancer. The study used mouse models to show that inhibiting a protein called SMYD3, along with cyclophosphamide, stopped tumors in their tracks.
First-line pembrolizumab or placebo combined with etoposide and platinum for ES-SCLC: KEYNOTE-604 Long-Term
The KEYNOTE-604 study shows that pembrolizumab-based combination with etoposide and platinum significantly improves progression-free survival and overall survival in patients with previously untreated ES-SCLC. Long-term follow-up data also reveal durable responses and manageable safety profiles.